VBI Vaccines Inc. (VBIV) and Its Rivals Financial Results Comparison

We are contrasting VBI Vaccines Inc. (NASDAQ:VBIV) and its competitors on their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. They are Biotechnology companies, competing one another.

Institutional & Insider Ownership

VBI Vaccines Inc. has 55.58% of its shares held by institutional investors vs. an average of 53.20% institutional ownership for its competitors. 12% of VBI Vaccines Inc. shares are held by company insiders. Comparatively, 8.45% of all Biotechnology companies shares are held by company insiders.


On first table we have VBI Vaccines Inc. and its peers’ return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
VBI Vaccines Inc. 16,624,243,364.89% 0.00% 0.00%
Industry Average 812.10% 105.95% 28.39%

Valuation and Earnings

In next table we are contrasting VBI Vaccines Inc. and its peers’ top-line revenue, valuation and net profit.

Net Income Gross Revenue Price/Earnings Ratio
VBI Vaccines Inc. 107.11M 1 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Ratings

Table 3 shows summary of recent ratings for VBI Vaccines Inc. and its peers.

Sell Ratings Hold Ratings Buy Ratings Rating Score
VBI Vaccines Inc. 0 0 2 3.00
Industry Average 1.10 1.78 2.39 2.81

VBI Vaccines Inc. currently has an average price target of $4, suggesting a potential upside of 395.60%. As a group, Biotechnology companies have a potential upside of 168.37%. With higher possible upside potential for VBI Vaccines Inc.’s peers, equities research analysts think VBI Vaccines Inc. is less favorable than its peers.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of VBI Vaccines Inc. and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
VBI Vaccines Inc. -7.83% -30.3% -61.68% -55.37% -66.43% -54.26%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year VBI Vaccines Inc. had bearish trend while VBI Vaccines Inc.’s competitors had bullish trend.


VBI Vaccines Inc. does not pay a dividend.


On 3 of the 4 factors VBI Vaccines Inc.’s peers beat VBI Vaccines Inc.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.